Compounded tirzepatide in the Philippines: what it is

Tirzepatide is one molecule, a dual GIP and GLP-1 receptor agonist. What differs between the three products below is who makes it, whether a regulator has registered it, and who is accountable for what is in the pen or vial.

In the Philippines, tirzepatide is registered only as Mounjaro, with 12 certificates of product registration on the FDA verification portal covering the KwikPen and single-dose vial presentations, each a prescription drug. Zepbound, Lilly's other tirzepatide brand, has no Philippine registration on the portal. Current pharmacy prices by pen strength are on the Mounjaro price Philippines page, and the molecule, its trials and how it is supplied are in the tirzepatide Philippines guide. Mounjaro is a prescription medicine, and prescribing belongs with a licensed Philippine physician.

Compounding means a pharmacy prepares a medicine for a prescription instead of a manufacturer producing a registered product. On 23 September 2026, 2 Philippine telehealth programs on this site's tracker named compounded tirzepatide on their own pages: GoRocky Weight Management and &you (andyou.ph) Care Plan. Their own disclaimers describe it plainly:

• &you (andyou.ph) Care Plan: Our tirzepatide is compounded by a licensed pharmacy. It is not FDA-approved
• &you (andyou.ph) Care Plan: Compounded medications are not reviewed or approved by the FDA for safety or effectiveness.

The disclaimers do not say which FDA they mean. The programs' prices, what each fee includes and where their own pages contradict themselves are on the GLP-1 telehealth tracker.

A research-grade vial is lyophilized tirzepatide sold as laboratory material. It is not compounded for a patient, not dispensed against a prescription and not a medicine, and it is not a substitute for a prescribed pen. FDA Philippines has issued 3 warnings against unregistered tirzepatide products:

• FDA Advisory No. 2026-1019, 4 September 2026: The FDA warned the public against buying or using the unregistered drug product Peptatide Tirzepatide 15mg sold with Peptatide bacteriostatic water, which has no Certificate of Product Registration.
• FDA Advisory No. 2026-1020, 4 September 2026: The FDA warned the public against buying or using an unregistered 30 mg multi-use tirzepatide vial sold with bacteriostatic water, which has no Certificate of Product Registration.
• FDA Advisory No. 2026-0814, 30 July 2026: The FDA warned the public against buying or using the unregistered drug product Tirz Laine Tirzepatide 30mg/3 mL 99% Purity, which has no Certificate of Product Registration.

What the research on tirzepatide found, and its regulatory status in the US and EU, are on the tirzepatide compound page.

Section 11(a) of RA 3720 as amended by RA 9711 prohibits the manufacture, importation, sale, distribution, promotion or advertising of any health product that is unregistered, adulterated or misbranded. This site's legal research, checked 23 September 2026, found no FDA Philippines or DOH issuance that addresses compounded GLP-1 medicines by name. News outlets reported a Philippine College of Physicians advisory in March 2026, but this site’s legal research found no primary document for it, so this page does not quote it. The full framework is on the regulation hub. This is general information, not legal advice.

These follow from the gaps above. They are questions for the prescriber and the program, not medical advice.

• Which pharmacy compounds the product, and does it hold an FDA Philippines License to Operate?
• Does the product itself have a Certificate of Product Registration, and if not, on what basis is it dispensed?
• Is a certificate of analysis available for the batch, naming the laboratory, the batch number and what the test covered?
• Why a compounded product rather than the registered medicine, and does the physician document that choice?

Head-to-head evidence between the two registered GLP-1 medicines is on Mounjaro vs Ozempic. Prescribing belongs with a licensed Philippine physician.